Attorneys for investors in Danish pharmaceutical giant Novo Nordisk have requested nearly a third of a $100 million settlement that, if approved, would resolve claims the company hurt shareholders by failing to disclose "increasingly large kickbacks" it allegedly paid pharmacy benefit managers to get its products on lists of drugs recommended to providers.